Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
Stem cells show particular promise in treating diseases for which few other effective treatments exist.
Transplanting blood stem cells is a new but incredibly successful treatment for multiple sclerosis. Now, a study directed by the University of Zurich has looked closely at how the autoimmune disease is controlled by the treatment and how the immune system recovers afterward.
UC Davis Comprehensive Cancer Center has launched a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside.
A new Cleveland Clinic study has uncovered vital information about the cellular interaction of tumor cells and normal tissue, leading to a better understanding of how therapeutic resistance evolves.
The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).
Professor Dr Anton Henssen of Charité – Universitätsmedizin Berlin and the Helmholtz Association’s Max Delbrück Center (MDC) for Molecular Medicine, along with a group of researchers from the United States and the United Kingdom, have received a grant for a Cancer Grand Challenge.
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.
One in every two people will acquire cancer at some point in their lives, according to the most recent international estimate.
The mystery is being unraveled of why the control centers, or nuclei, of certain blood cancer cells have a distinctly odd shape.
The reason why the control centers, or nuclei, of certain blood cancer cells, have a peculiar structure is still a mystery.
Drug resistance is a major obstacle in the treatment of cancers. In an aggressive type of pancreatic cancer, for instance, drug resistance is associated with the suppression of programmed cell death, which results in the uncontrolled growth of cancer cells.
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell's Ithaca campus.
Metabolic reprogramming, accepted as a hallmark of cancer, might indicate a vulnerability to be used by targeted cancer therapy.
Mount Sinai researchers have solved a major mystery in cancer research: How cancer cells remain dormant for years after they leave a tumor and travel to other parts of the body, before awakening to create metastatic cancer.
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.
Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.
In the late 1980s, scientists developed a revolutionary approach to treating acute myeloid leukemia (AML), a type of blood cancer. Called differentiation therapy, it amounted to a bona fide cure for many patients.
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
Carolina Liquid Chemistries Corp. has introduced a new line of laboratory water systems to the USA market.
A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients' brain tumors.